Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;261(3):561-9.
doi: 10.1007/s00415-013-7235-1. Epub 2014 Jan 30.

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease

María T Cáceres-Redondo  1 , Fátima Carrillo, María J Lama, Ismael Huertas-Fernández, Laura Vargas-González, Manuel Carballo, Pablo Mir
Affiliations

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease

María T Cáceres-Redondo et al. J Neurol. 2014 Mar.

Abstract

The short-term benefits of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson's disease (PD) are well documented, but the long-term benefits are still uncertain. The aim of this study was to investigate the motor and cognitive outcome of LCIG treatment in advanced PD after a follow-up period of at least 24 months. We assessed 29 patients with advanced PD who started LCIG infusion at our centre between 2007 and 2013. Motor fluctuations, parkinsonian symptoms, activities of daily living and impact on quality of life were evaluated. We also investigated the cognitive outcome using a battery of neuropsychological tests. All adverse events were recorded. Of the 29 PD patients who initiated LCIG, 16 patients reached the follow-up evaluation (24 months), after a mean time period of 32.2 ± 12.4 months. Six patients did not fulfil the 24-month follow-up visit and were evaluated after a mean time period of 8.6 ± 5.4 months. Seven patients discontinued the treatment before the scheduled visit. "Off" time and "On" dyskinesia duration were significantly reduced. LCIG improved quality of life and non motor symptoms, despite overall unchanged total levodopa doses prior to LCIG beginning. Motor and cognitive decline were detected. A relatively high number of adverse events occurred during the follow-up, above all, technical problems with the infusion device and mild problems related with gastrostomy. There were four cases of peripheral neuropathy (PN), 2 of which were considered serious. Our data confirm that LCIG is beneficial in the long-term treatment of advanced PD patients despite a decline in cognitive functions in a subgroup of patients, probably due to disease progression. PN in patients with LCIG may be more frequent than the published date suggest.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Neurol. 2002 Feb;249(2):138-45 - PubMed
    1. Mov Disord. 2008 Oct 15;23(13):1850-9 - PubMed
    1. Ann Neurol. 2010 Jul;68(1):28-36 - PubMed
    1. Brain. 2000 Nov;123 ( Pt 11):2297-305 - PubMed
    1. Parkinsonism Relat Disord. 2013 May;19(5):501-7 ; discussion 501 - PubMed

Publication types

MeSH terms

LinkOut - more resources